Background: The b-lactamase landscape is changing radically, with CTX-M types now the most prevalent extended-spectrum b-lactamases (ESBLs) worldwide, except maybe in the USA. In addition, there are growing numbers of Enterobacteriaceae with KPC and metallo-carbapenemases. We examined whether combinations of oxyimino-cephalosporins with NXL104, a novel non-b-lactam b-lactamase inhibitor, overcame these resistances.
Introduction
NXL104 (Novexel) is a novel-structure b-lactamase inhibitor ( Figure 1 ). It was shown previously to inhibit AmpC and TEM/ SHV-type extended-spectrum b-lactamases (ESBLs), potentiating cephalosporins against producers. 1 However, the b-lactamase landscape is now changing radically. CTX-M enzymes, rather than TEM and SHV mutants, are increasingly the predominant ESBLs in Europe and Asia, 2,3 with this replacement perhaps now beginning also in North America. 4 Other ESBLs are locally frequent, for example, PER enzymes in Turkey and Argentina 5, 6 and VEB types in the East Asia. In addition, there is a slow emergence of carbapenem resistance in Enterobacteriaceae. Some of this is due to porin loss-often unstable-in ESBL-and AmpC-producing strains, 7 more worryingly, though, true carbapenemases are also gradually accumulating. Specifically, (i) Klebsiella pneumoniae clones with KPC carbapenemases are spreading across the USA, Colombia and Israel 8, 9 with scattered reports from Europe and China; (ii) there are clusters of Enterobacteriaceae isolates with metallocarbapenemases in southern Europe and Asia; and (iii) there are multiple reports of Enterobacteriaceae with OXA-48, a weak carbapenemase in Turkey.
We assessed the activity of NXL104 combined with cefotaxime and ceftazidime against these increasingly important resistance types. 
Results and discussion
MICs for Enterobacteriaceae transconjugants with the three most prevalent CTX-M ESBLs in Europe (i.e. CTX-M-9, 14 and -15, also PER-1) are shown in Table 1 , whereas those for carbapenemsusceptible clinical isolates with various CTX-M enzymes are shown in Table 2 , sorted by the enzyme group. The potentiation of cefotaxime by NXL104 generally exceeded 1000-fold for isolates with CTX-M enzymes, with MICs reduced from 128 to 0.03 to 0.12 mg/L. MICs of ceftazidime for isolates Klebsiella spp. (7) and E. coli (4) with IMP and VIM metallo-b-lactamases cefotaxime 11 cefotaxime þ NXL104 11 ceftazidime 11 ceftazidime þ NXL104 11
with CTX-M-15 enzyme were reduced from (generally) 64 to 0.25-1 mg/L; those for isolates with other CTX-M types, which generally confer lower levels of ceftazidime resistance than CTX-M-15, were reduced from 2-8 to 0.12-1 mg/L. When tested against ertapenem-resistant (MIC .2 mg/L) Enterobacteriaceae isolates that had combinations of CTX-M or AmpC enzymes together with impermeability, NXL104 reduced cefotaxime MICs to 2 mg/L and those of ceftazidime to 4 mg/L. Imipenem MICs ranged up to 64 mg/L for these organisms (Table 2) .
MIC data for Enterobacteriaceae isolates and transconjugants with carbapenemases are shown in Table 3 . NXL104 reduced cefotaxime MICs from .128 to 0.5 mg/L for most isolates with KPC enzymes and those of ceftazidime from 128 to 4 mg/L. The sole exception was Enterobacter aerogenes E624, which had KPC-4 enzyme, derepressed AmpC and porin loss, where the cefotaxime and ceftazidime MICs were reduced to 1 and 32 mg/L, respectively. In view of the good activity of the cefotaxime þ NXL104 combination, it seems likely that the high MIC of ceftazidime þ NXL104 reflected this combination of factors, rather than any specific trait of the KPC-4 enzyme.
A Serratia marcescens isolate with SME-1 carbapenemase was not substantially resistant to cefotaxime and ceftazidime, as is typical of the phenotype; nevertheless, the cefotaxime MIC was reduced 4-fold in the presence of NXL104. Good synergy was seen for four Turkish isolates with OXA-48 enzyme-one E. coli and three K. pneumoniae-in which MICs of cefotaxime and ceftazidime generally were reduced from .64 to 2 mg/L. NXL104 achieved no significant reduction of the MICs of cefotaxime and ceftazidime for metallo-b-lactamase producers with IMP and VIM enzymes.
Taken as a whole, the activity of cephalosporin þ NXL104 combinations against isolates and transconjugants with ESBLs and non-metallo-carbapenemases was impressive. Such combinations may provide a future alternative to carbapenems in infections due to ESBL, which are growing problems worldwide, and may also provide a route to overcoming isolates with carbapenem resistance contingent on KPC b-lactamasesanother growing problem. The utility of these combinations depends, of course, on satisfactory pharmacokinetics, where phase I data show that a single 500 mg dose of NXL104 gave a C max of 10 mg/L with a t 1/2 of 1.8 h. 11 The lack of activity against metallo-b-lactamase producers is a limitation but might be overcome by combining NXL104 with a monobactam, as these compounds are stable to class B enzymes.
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